CI vs ZBH: fair value comparison
The Cigna Group and Zimmer Biomet Holdings, Inc. · Updated 2026-09-06
Both currently screen as undervalued on TickrTrends' Forward Fair Value model. Within Healthcare, CI currently sits closer to the top of our discount ranking. ZBH carries the stronger quality grade.
| CI | ZBH | |
|---|---|---|
| Verdict | Undervalued | Undervalued |
| Last price | $282.52 | $98.07 |
| 12-month range | $244.41–$289.26 | $82.90–$100.56 |
| Sector rank | #34 of 113 Healthcare | #39 of 113 Healthcare |
| Quality grade | F | B |
| Momentum grade | — | B |
| Leverage | Moderate | Moderate |
| Margin trend | Contracting | Stable |
| Revenue growth | Strong | Modest |
| RSI zone | Neutral | Neutral |
| DCF cross-check | Undervalued | Undervalued |
| 52-week position | The top quarter | The top quarter |
Full single-stock breakdowns: CI fair value analysis · ZBH fair value analysis